PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature Reviews Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrendo.2010.89PMID 20567246
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors

  2010cited by this paper
• Residual microvascular risk in diabetes: unmet needs and future directions

  2010cited by this paper
• Proliferative retinopathies: angiogenesis that blinds.

  2010cited by this paper
• Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

  2009cited by this paper
• Peroxisome proliferator-activated receptors and angiogenesis.

  2009cited by this paper
• Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes

  2009cited by this paper
• Remodeling of Retinal Fatty Acids in an Animal Model of Diabetes

  2009cited by this paper
• Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy

  2009cited by this paper
• Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

  2009cited by this paper
• Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

  2009cited by this paper
• Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology.

  2009cited by this paper
• Saturated with fat: new perspectives on lipotoxicity

  2009cited by this paper
• Abnormal Angiogenesis in Diabetic Nephropathy

  2009cited by this paper
• Activation and signaling by the AMP-activated protein kinase in endothelial cells.

  2009cited by this paper
• Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.

  2009cited by this paper
• Inflammatory, Hemostatic, and Other Novel Biomarkers for Diabetic Retinopathy

  2009cited by this paper
• Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

  2009cited by this paper
• Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes

  2009cited by this paper
• Dyslipidemia-Induced Neuropathy in Mice

  2009cited by this paper
• Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes

  2009cited by this paper
• Fibrates and microvascular complications in diabetes--insight from the FIELD study.

  2009cited by this paper
• Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications.

  2009cited by this paper
• Advances in the Medical Treatment of Diabetic Retinopathy

  2009cited by this paper
• The treatment of hyperhomocysteinemia.

  2009cited by this paper
• An update on the lipid nephrotoxicity hypothesis

  2009cited by this paper
• Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

  2008cited by this paper
• Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes.

  2008cited by this paper
• Fenofibrate Treatment of Diabetic Rats Reduces Nitrosative Stress, Renal Cyclooxygenase-2 Expression, and Enhanced Renal Prostaglandin Release

  2008cited by this paper
• Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

  2008cited by this paper
• Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?

  2008cited by this paper
• Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat

  2008cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition

  2008cited by this paper
• Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol.

  2008cited by this paper
• Images in clinical medicine. Paget's disease of the mandible.

  2008cited by this paper
• Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.

  2008cited by this paper
• PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.

  2008cited by this paper
• Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years

  2008cited by this paper
• Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia.

  2008cited by this paper
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

  2008cited by this paper
• Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications

  2008cited by this paper
• Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Microvascular disease: what does the UKPDS tell us about diabetic retinopathy?

  2008cited by this paper
• Cortical Expression of Peroxisome Proliferator-activated Receptor-α after Human Brain Contusion

  2008cited by this paper
• The role of inflammatory cytokines in diabetic nephropathy.

  2008cited by this paper
• Physiological regulation of prostaglandins in the kidney.

  2008cited by this paper
• A PPARs cross‐talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis

  2008cited by this paper
• Nitric oxide: Ocular blood flow, glaucoma, and diabetic retinopathy

  2007cited by this paper
• Genetic factors in diabetic nephropathy.

  2007cited by this paper
• Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.

  2007cited by this paper
• Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

  2007cited by this paper
• Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway.

  2007cited by this paper
• Role of Redox Reactions in the Vascular Phenotype of Hyperhomocysteinemic Animals

  2007cited by this paper
• Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

  2007cited by this paper
• Peroxisome proliferator‐activated receptor‐α agonist fenofibrate regulates IL‐12 family cytokine expression in the CNS: relevance to multiple sclerosis

  2007cited by this paper
• Peroxisome proliferator‐activated receptor‐alpha is required for the neurotrophic effect of oleic acid in neurons

  2007cited by this paper
• The renin-angiotensin system and diabetic nephropathy.

  2007cited by this paper
• Mechanisms of Homocysteine-Induced Glomerular Injury and Sclerosis

  2007cited by this paper
• Inflammatory mechanisms of diabetic complications

  2007cited by this paper
• Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes.

  2007cited by this paper
• PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

  2006cited by this paper
• Nitric oxide in the kidney: functions and regulation of synthesis

  2006cited by this paper
• Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

  2006cited by this paper
• Elevated Homocysteine Reduces Apolipoprotein A-I Expression in Hyperhomocysteinemic Mice and in Males With Coronary Artery Disease

  2006cited by this paper
• C-Reactive Protein as a Predictor of Incident Ischemic Stroke Among Patients With Preexisting Cardiovascular Disease

  2006cited by this paper
• Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

  2006cited by this paper
• Serum lipids and the progression of nephropathy in type 1 diabetes.

  2006cited by this paper
• Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes

  2006cited by this paper
• Peroxisome Proliferator-activated Receptor α Interacts with High Affinity and Is Conformationally Responsive to Endogenous Ligands*

  2005cited by this paper
• The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina.

  2005cited by this paper
• Vascular risk factors and diabetic neuropathy.

  2005cited by this paper
• Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

  2005cited by this paper
• Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease.

  2005cited by this paper
• The pathobiology of diabetic complications: a unifying mechanism.

  2005cited by this paper
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26.

  2004cited by this paper
• NO Pain: Potential Roles of Nitric Oxide in Neuropathic Pain

  2004cited by this paper
• Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain.

  2004cited by this paper
• Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.

  2004cited by this paper
• PPAR&agr; Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation

  2004cited by this paper
• Peroxisome-proliferator-activated receptors and cancers: complex stories

  2004cited by this paper
• Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.

  2004cited by this paper
• Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney.

  2004cited by this paper
• Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study.

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor-α Activation as a Mechanism of Preventive Neuroprotection Induced by Chronic Fenofibrate Treatment

  2003cited by this paper
• Energy metabolism and cytotoxicity.

  2003cited by this paper
• Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments.

  2003cited by this paper
• Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.

  2003cited by this paper
• Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study

  2002cited by this paper
• Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.

  2002cited by this paper
• The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

  2002cited by this paper
• Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.

  2002cited by this paper
• Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.

  2002cited by this paper
• Long-term n-3 FA deficiency modifies peroxisome proliferator-activated receptor β mRNA abundance in rat ocular tissues

  2002cited by this paper
• Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine

  2002cited by this paper
• Endothelium-dependent and independent vasodilation studied at normoglycaemia in Type I diabetes mellitus with and without microalbuminuria

  2001cited by this paper
• Gemfibrozil improves insulin sensitivity and flow‐mediated vasodilatation in type 2 diabetic patients

  2001cited by this paper
• Risk factors for renal failure: the WHO Mulinational Study of Vascular Disease in Diabetes.

  2001cited by this paper

• Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy

  2026cites this paper
• Oxybaphus himalaicus alleviates diabetic kidney disease by suppressing the lipid metabolism and inflammation via PPARα signaling.

  2025cites this paper
• Mechanism Analysis of Zuogui and Yougui Pills on Diabetic Nephropathy Through Transcriptional Regulatory Networks of HIF1A and PPARA

  2025cites this paper
• Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?

  2025cites this paper
• Targeting lipid metabolic reprogramming to alleviate diabetic kidney disease: molecular insights and therapeutic strategies

  2025cites this paper
• Mechanism of PPARα agonist in alopecia areata.

  2025cites this paper
• Current Perspectives of Mitochondria in Sepsis-Induced Cardiomyopathy

  2024cites this paper
• Progress based on a multi-omics research strategy in the biosynthesis and modernization of active ingredients of Herpetospermum pedunculosum seeds.

  2024cites this paper
• Clickable Corneal Neovascularization Therapy with ROS-Responsive Polydopamine Silica Nanoparticles Loaded with Fenofibrate

  2023cites this paper
• Cyanidin-3-O-glucoside as a Nutrigenomic Factor in Type 2 Diabetes and Its Prominent Impact on Health

  2023cites this paper
• The role of protein kinase C in diabetic microvascular complications

  2022cites this paper
• The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

  2022cites this paper
• Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.

  2022influential citation
• Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway

  2022cites this paper
• Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice

  2022cites this paper
• Simultaneous Presentation of Multiple Myeloma and Lung Cancer: Case Report and Gene Bioinformatics Analysis

  2022cites this paper
• Cardiac Metabolism in Sepsis

  2021cites this paper
• Nuclear Receptors in Liver Fibrosis.

  2021cites this paper
• Alkaloidal extract from Zanthoxylum zanthoxyloides stimulates insulin secretion in normoglycemic and nicotinamide/streptozotocin-induced diabetic rats

  2021cites this paper
• Metabolic Alterations in Sepsis

  2021cites this paper
• Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy

  2021cites this paper
• Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina

  2020cites this paper
• Diagnostic methods and pharmacological management of non-alcoholic fatty liver disease – There is still room for improvement

  2020cites this paper
• Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia

  2020cites this paper
• Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy

  2020cites this paper
• Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina

  2020cites this paper
• Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine.

  2020cites this paper
• PPARα Agonist Oral Therapy in Diabetic Retinopathy

  2020cites this paper
• A dietary anthocyanin cyanidin-3-O-glucoside binds to PPARs to regulate glucose metabolism and insulin sensitivity in mice

  2020cites this paper
• Tongxinluo attenuates oxygen-glucose-serum deprivation/restoration-induced endothelial barrier breakdown via peroxisome proliferator activated receptor-α/angiopoietin-like 4 pathway in high glucose-incubated human cardiac microvascular endothelial cells

  2020cites this paper
• PPARα activation directly upregulates thrombomodulin in the diabetic retina

  2020cites this paper
• Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

  2020cites this paper
• MiR-34a regulates the glucose metabolism of Blunt snout bream (Megalobrama amblycephala) fed high-carbohydrate diets through the mediation of the Sirt1/FoxO1 axis

  2019cites this paper
• Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

  2019cites this paper
• Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model

  2019cites this paper
• Nonproliferative Diabetic Retinopathy

  2018cites this paper
• Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review

  2018cites this paper
• Fenofibrate Ameliorates Oxidative Stress-Induced Retinal Microvascular Dysfunction in Diabetic Rats

  2018cites this paper
• Naoxintong restores collateral blood flow in a murine model of hindlimb ischemia through PPARδ-dependent mechanism.

  2018cites this paper
• Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?

  2018cites this paper
• Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy

  2017cites this paper
• Schwann cell interactions with axons and microvessels in diabetic neuropathy

  2017cites this paper
• Irisin-Processor Gene: Molecular Structure,Expressive Regulation,Biological Functions and the Associations with Skeletal Muscle Fiber Types

  2016cites this paper
• Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging.

  2016cites this paper
• Lipids and Diabetic Retinopathy

  2016influential citation
• Plasma Periostin Levels Are Increased in Chinese Subjects with Obesity and Type 2 Diabetes and Are Positively Correlated with Glucose and Lipid Parameters

  2016cites this paper
• to combat

  2016cites this paper
• The in Silico Study of Nutmeg Seeds (Myristica fragrans Houtt) as Peroxisome Proliferator Activated Receptor Gamma Activator Using 3D-QSAR Pharmacophore Modelling

  2016cites this paper
• Regulation of NF-κB signalling cascade by immunophilins.

  2015cites this paper
• Restoration of Endothelial Function in Pparα −/− Mice by Tempol

  2015cites this paper
• Fenofibrate enhances barrier function of endothelial continuum within the metastatic niche of prostate cancer cells

  2015cites this paper
• Therapeutic Effects of PPARα on Neuronal Death and Microvascular Impairment

  2015cites this paper
• Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells

  2015cites this paper
• PPAR-α agonist regulates amyloid-β generation via inhibiting BACE-1 activity in human neuroblastoma SH-SY5Y cells transfected with APPswe gene

  2015cites this paper
• Beneficial Health Effects of Chios Gum Mastic and Peroxisome Proliferator-Activated Receptors: Indications of Common Mechanisms

  2015cites this paper
• Men and women differ in their diurnal expression of monocyte peroxisome proliferator‐activated receptor‐α in the fed but not in the fasted state

  2015cites this paper
• Role of peroxisome proliferator-activated receptor α in atherosclerosis.

  2014influential citation
• The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARγ, RORs, and Rev-erbs.

  2014cites this paper
• Wogonin ameliorates hyperglycemia and dyslipidemia via PPARα activation in db/db mice.

  2014cites this paper
• Irisin impact as a medication that ameliorate and hinder the development of insulin resistance associated disorders without regular exercise (experimental study)

  2014cites this paper
• PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.

  2014cites this paper
• Association of endothelial lipase Thr111Ile polymorphism with proliferative retinopathy in type 2 diabetes patients.

  2014cites this paper
• Protective and antioxidant effects of PPARα in the ischemic retina.

  2014cites this paper
• Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.

  2014cites this paper
• Effect of Combined Fenofibrate and Nicotinamide on Oxidative Stress and Inflammatory Cytokines Involved in Cisplatin-Induced Nephrotoxicity in Rats

  2014cites this paper
• Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits

  2014cites this paper
• Influence of Fenofibrate Treatment on Triacylglycerides, Diacylglycerides and Fatty Acids in Fructose Fed Rats

  2014cites this paper
• Fenofibrate Attenuated Glucose-Induced Mesangial Cells Proliferation and Extracellular Matrix Synthesis via PI3K/AKT and ERK1/2

  2013cites this paper
• Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes

  2013cites this paper
• Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction

  2013cites this paper
• Hepatic PPARs: their role in liver physiology, fibrosis and treatment.

  2013cites this paper
• Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study

  2013cites this paper
• Fenofibrate and the kidney: an overview

  2013cites this paper
• Redox-inflammatory synergy in the metabolic syndrome.

  2013cites this paper
• Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

  2013cites this paper
• A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis

  2013cites this paper
• 6. Diabetes Drugs

  2013cites this paper
• PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

  2013cites this paper
• Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan.

  2013cites this paper
• Molecular docking of Glyceroneogenesis pathway intermediates with Peroxisome Proliferator- Activated Receptor-Alpha (PPAR-α)

  2013cites this paper
• Structural Features and Transcriptional Activity of Chicken PPARs (α, β, and γ)

  2013cites this paper
• Small Heterodimer Partner-Targeting Therapy Inhibits Systemic Inflammatory Responses through Mitochondrial Uncoupling Protein 2

  2013cites this paper
• Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models

  2012cites this paper
• Biology and therapeutic applications of peroxisome proliferator- activated receptors.

  2012cites this paper
• Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes

  2012cites this paper
• Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

  2012cites this paper
• Gene, pathway and network frameworks to identify epistatic interactions of single nucleotide polymorphisms derived from GWAS data

  2012cites this paper
• From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity

  2012cites this paper
• Quercetin and Allopurinol Ameliorate Kidney Injury in STZ-Treated Rats with Regulation of Renal NLRP3 Inflammasome Activation and Lipid Accumulation

  2012cites this paper
• International Evaluation of Research and Doctoral Training at the University of Helsinki 2005-2010: RC-Specific Evaluation of CompDisGen - Complex Disease Genomics Group

  2012cites this paper
• The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

  2012cites this paper
• A silent partner no longer – sinusoidal endothelial cells in liver homeostasis and disease.

  2012cites this paper
• PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

  2012cites this paper
• Egr-1 contributes to IL-1-mediated down-regulation of peroxisome proliferator-activated receptor γ expression in human osteoarthritic chondrocytes

  2012cites this paper
• DB110413 261..272

  2012cites this paper
• Beta-D-glucoside protects against advanced glycation end products (AGEs)-mediated diabetic responses by suppressing ERK and inducing PPAR gamma DNA binding.

  2012cites this paper
• Serum Apolipoproteins Are Associated With Systemic and Retinal Microvascular Function in People With Diabetes

  2012cites this paper
• Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways.

  2011cites this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cites this paper
• Diabetes mellitus Typ 2 und Niere: Die Rolle der Insulinresistenz

  2011cites this paper